Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: AbbVie | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: AbbVie

Revenues down 2% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie
 
4Q Revenues: $5.1 billion (-2%)
 
4Q Earnings: $1.1 billion (-27%)
 
FY Revenues: $18.8 billion (+2%)
 
FY Earnings: $4.1 billion (-22%)
 
Comments: Global Humira sales increased 13% to $3.0 billion in the quarter. U.S. Humira sales grew 18% to $1.7 billion. Synagis sales were $314 million, down 6%. AndroGel sales were down 21% to $289 million. Kaletra sales were $228 million, down 9%. Lupron sales were $209 million, down 1%. Synthroid sales were up 13% to $189 million. Niaspan and TriCor/Trilipix sales were down 89% and 85% respectively, due to generic competition. R&D expenses were up 17% to $798 million in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters